STOCK TITAN
  1. Home
  2. News
  3. TMCI

Treace Medical Concepts, Inc. - TMCI STOCK NEWS

Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.

Treace Medical Concepts, Inc. is a leading orthopaedic medical device company specializing in innovative solutions for the surgical management of bunion deformities. With a commitment to excellence, the company brings breakthrough technologies to the high-growth $1.1 billion US market for foot and ankle surgical products.

Treace's flagship product, the Lapiplasty® 3D Bunion Correction™ procedure, addresses the root cause of bunions by correcting all planes of the deformity. This patented procedure not only improves patient outcomes but also allows for a quicker return to an active lifestyle.

The company operates as a single segment, focusing on the design, manufacturing, and marketing of medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals. Their mission is to assist foot and ankle physicians in enhancing patient outcomes and reducing healthcare costs, while also providing a rewarding experience for their employees and exceptional returns for shareholders.

In recent news, Treace Medical Concepts announced their participation in the upcoming J.P. Morgan Healthcare Conference, showcasing new SpeedPlate™ configurations, and the full commercial release of the Micro-Lapiplasty™ System. Additionally, they have initiated a limited clinical release of the Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation. The company also focuses on educational outreach to build awareness and reduce stigma around bunion deformities.

Treace Medical Concepts has also partnered to support pickleball players with bunions and related midfoot deformities, helping them to 'get back on their feet' and onto the court. Such initiatives highlight Treace's dedication to improving the lives of individuals affected by foot health issues.

News

Treace to Present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Treace Medical Concepts, Inc. (TMCI) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, at 3:45 pm Pacific Time. The CEO will discuss the company's flagship Lapiplasty® and Adductoplasty® Procedures. The webcast and replay will be available on the investor relations website. Treace routinely posts important information for investors on its website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.24%
Tags
conferences
-
News

Treace Medical Concepts Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) reported a 23% increase in revenue to $40.8 million for the third quarter of 2023. The company also achieved a 36% year-to-date increase in revenue. The gross margin was 80.4% in the third quarter, and 81.0% year to date. Treace has expanded its patent portfolio to 52 granted U.S. patents, with additional patents worldwide and pending U.S. patent applications. The CEO, John T. Treace, highlighted a 21% increase in the surgeon base and a record blended average selling price of $6,311.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.9%
Tags
earnings
-
News

Treace to Present at Stifel 2023 Healthcare Conference

Rhea-AI Summary
Treace Medical Concepts, Inc. (TMCI) will participate in a fireside chat at the Stifel 2023 Healthcare Conference on November 14, 2023. The CEO and CFO will discuss the Lapiplasty® 3D Bunion Correction® Procedure. A live webcast and replay will be available on the investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
conferences
News

Treace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023

Rhea-AI Summary
Treace Medical Concepts, Inc. will present new interim data for the ALIGN3D™ clinical study at the AOFAS Annual Meeting. The data shows early return to weight bearing in 8.4 days, low recurrence rate, and 81% reduction in pain. The company also highlights new product innovations, including the SpeedPlate™ and Micro-Lapiplasty™ technologies. Full commercial launch of these technologies is expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
clinical trial
-
News

Treace Medical Concepts Announces New Patent Covering Instrumented Bunion Correction Procedures and Milestone 50th U.S. Patent

Rhea-AI Summary
Treace Medical Concepts, Inc. announces forthcoming issuance of U.S. Patent No. 11,771,467 for bunion correction procedure
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.89%
Tags
none
-
News

Treace Medical Concepts Announces Limited Market Release of New Complementary Technologies for Treating Bunions and Related Procedures

Rhea-AI Summary
Treace Medical Concepts expands market opportunity with new technologies for treating bunions and bunion-related procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.18%
Tags
none
News

Treace Announces Participation in the 21st Annual Morgan Stanley Global Healthcare Conference

Rhea-AI Summary
Treace Medical Concepts, Inc. will participate in a fireside chat at the 21st Annual Morgan Stanley Global Healthcare Conference on September 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
-
News

Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

Rhea-AI Summary
Treace Medical Concepts appoints Nathan Minnich as Sr. Vice President of Marketing to expand physician outreach and patient awareness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
management
-
News

Treace Medical Concepts Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) reported a 40% increase in revenue to $42.0 million in Q2 2023. The gross margin was 81.7%, and revenue from direct sales increased to 79% of sales. The company also completed an acquisition and expanded its patent portfolio. The CEO highlighted the growth in sales reps and expected market penetration for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.36%
Tags
earnings
News

Treace Announces Participation in the UBS Medtech, Tools and Genomics Summit 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
none

FAQ

What is the current stock price of Treace Medical Concepts (TMCI)?

The current stock price of Treace Medical Concepts (TMCI) is $10.51 as of February 4, 2025.

What is the market cap of Treace Medical Concepts (TMCI)?

The market cap of Treace Medical Concepts (TMCI) is approximately 636.4M.

What does Treace Medical Concepts, Inc. specialize in?

Treace Medical Concepts specializes in innovative solutions for the surgical management of bunion deformities.

What is the Lapiplasty® 3D Bunion Correction™ procedure?

The Lapiplasty® 3D Bunion Correction™ procedure is designed to correct all planes of a bunion deformity, addressing its root cause and allowing for quick patient recovery.

What recent products has Treace Medical Concepts released?

Treace has released the Micro-Lapiplasty™ System, SpeedPlate™ configurations, and introduced the Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation.

How does Treace Medical Concepts support the foot and ankle surgical market?

Treace supports this market by designing, manufacturing, and marketing medical devices that enhance patient outcomes and reduce healthcare costs.

When is Treace Medical Concepts presenting at the J.P. Morgan Healthcare Conference?

Treace Medical Concepts is presenting at the J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 3:45 pm Pacific Time.

What is Treace's focus regarding patient outcomes?

Treace aims to improve patient outcomes by providing innovative surgical solutions that address the root cause of bunion deformities and allow quicker recovery times.

Who are the primary customers of Treace Medical Concepts?

The primary customers include physicians, surgeons, ambulatory surgery centers, and hospitals.

What ethical standards does Treace Medical Concepts adhere to?

Treace prides itself on operating with the highest standards of ethical conduct in all its business operations.

What is the company’s mission?

The mission is to assist foot and ankle physicians in improving patient outcomes and reducing healthcare costs, while providing a rewarding experience for employees and exceptional returns for shareholders.

How is Treace Medical Concepts involved in community outreach?

Treace is actively involved in outreach and education efforts to build awareness, reduce stigma, and correct misconceptions about bunion deformities.
Stock TMCI logo
Treace Medical Concepts, Inc.

Nasdaq:TMCI

TMCI Rankings

#2926 Ranked by Market Cap
N/A Ranked by Dividends

TMCI Stock Data

636.36M
45.08M
26.1%
64.67%
3.64%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
PONTE VEDRA